Differential gene expression profiling in aggressive bladder transitional cell carcinoma compared to the adjacent microscopically normal urothelium by microdissection-SMART cDNA PCR-SSH

Cancer Biology and Therapy

Volumn 5, Issue 1, 2006, Pages 104-110

  Wang, H T ^a   Ma, F L ^a   Ma, X B ^b   Han, R F ^a   Zhang, Y B ^a   Chang, J W ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b NORTH CHINA COAL MEDICAL COLLEGE   (China)

Author keywords

Aggressive; Aggressive low malignant; Agressive bladder transitional cell carcinomas; Bladder transitional cell carcinomas; Differential gene expression; Microdissection; Normal urothelium; Suppressive subtractive hybridization

Indexed keywords

COMPLEMENTARY DNA;

ARTICLE; BLADDER CARCINOMA; CARCINOGENESIS; CONTROLLED STUDY; DATA BASE; DNA LIBRARY; DNA SEQUENCE; EXPRESSED SEQUENCE TAG; GENBANK; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INSERTION; HUMAN; HUMAN TISSUE; MICRODISSECTION; MICROSCOPY; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; TRANSITIONAL CELL CARCINOMA; UPREGULATION; UROTHELIUM;

EID: 32544438624     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.1.2348     Document Type: Article

References (56)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999; 49:8-31.
2. Koss LG. Bladder cancer from a perspective of 40 years. J Cell Biochem Suppl 1992; 16I:23-9.
3. Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: New correlations between observations and molecular mechanisms. Semin Urol 1993; 11:177-192.
4. Wang HT, Chang JW. Molecular pathology of low malignant bladder transitional cell carcinoma: A current perspective. Histol Histopathol 2005; 20:147-53.
5. Steinberg GD, Trump DL, Cummings KB. Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am 1992; 19:735-46.
6. Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 2000; 60:4021-5.
7. Forsti A, Louhelainen J, Soderberg M, Wijkstrom H, Hemminski K. Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer. Eur J Cancer 2001; 37:1372-80.
8. Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Obermann EC, Hammerschmied C, Wieland WT, Knuechel R, Hartmann A. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005; 47:58-63.
9. Tchernitsa OI, Zuber J, Sers C, Brinckmann R, Britsch SK, Adams V, Schafer R. Gene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators. Oncogene 1999; 18:5448-54.
10. Wentzensen N, Wilz B, Findeisen P, Wagner R, Dippold W, von Knebel Doeberitz M, Gebert J. Identification of differentially expressed genes in colorectal adenoma compared to normal tissue by suppression subtractive hybridization. Int J Oncol 2004; 24:987-94.
11. Croner RS, Guenther K, Foertsch T, Siebenhaar R, Brueckl WM, Stremmel C, Hlubek F, Hohenberger W, Reingruber B. Tissue preparation for gene expression profiling of colorectal carcinoma: Three alternatives to laser microdissection with preamplification. J Lab Clin Med 2004; 143:344-51.
12. Xu LL, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, Carter KC, Srivastava S. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol 2000; 163:972-9.
13. Hu SP, Zhang KH, Shen ZY, Wu MY, Deng XL, Yang JS, Fang FD. Manual microdissection of defined, cells and RNA extraction for gene expression analysis of esophageal carcinoma progress. Zhongguo Yi Xue Ke Xue Yuan Xue Bao (Chinese), 2003:25:659-63.
14. Sopov I, Sorensen T, Magbagbeolu M, Jansen L, Beer K, Kuhne-Heid R, Kirchmayr R, Schneider A, Durst M. Detection of cancer-related gene expression profiles in severe cervical neoplasia. Int J Cancer 2004; 112:33-43.
15. Diggle CP, Cruickshank S, Olsburgh JD, Pellegrin S, Smith B, Banks RE, Selby PJ, Knowles MA, Southgate J, Harnden P. Identification of genes upregulated in urothelial tumors: The 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol 2003; 163:493-504.
16. Mostofi FK, Davis CJ, Sesterhenn IA. World Health Organization. Histological Typing of Urinary Bladder Tumours. 2nd ed. Berlin: Springer-Verlag, 1999:4-8.
17. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998; 22:1435-48.
18. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD. Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 1996; 93:6025-30.
19. Altschul, Stephen F, Thomas Madden L, Alejandro Schäffer A, Jinghui Zhang, Zheng Zhang, Webb Miller, David Lipman J. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389-402.
20. Schalken JA, van Moorselaar RJ, Bringuier PP, Debruyne FM. Critical review of the models to study the biologic progression of bladder cancer. Semin Surg Oncol 1992; 8:274-8.
21. Elek J, Park KH, Narayanan R. Microarray-based expression profiling in prostate tumors. In Vivo 2000; 14:173-82.
22. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, Knuutila S. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002; 21:5804-13.
23. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD. Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 1996; 93:6025-30.
24. Schlaepfer DD, Mitra SK, Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 2004; 1692:77-102.
25. Wang LH. Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 2004; 71:361-7.
26. Meng TC, Lee MS, Lin MF. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 2000; 19:2664-77.
27. Lin JS, Lu CW, Huang CJ, Wu PF, Robinson D, Kung HJ, Chi CW, Wu CW, Yang WK, Whang-Peng JJ, Lin WC. Protein-tyrosine kinase and protein-serine/threonine kinase expression in human gastric cancer cell lines. J Biomed Sci 1998; 5:101-10.
28. Otto T, Goepel M, Recker F, Rubben H. Principles of tumor invasion and metastasis. Urologe A (German) 1995; 34:208-11.
29. Grossman HB, Lee C, Bromberg J, Liebert M. Expression of the alpha6beta4 integrin provides prognostic information in bladder cancer. Oncol Rep 2000; 7:13-6.
30. Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R, Cooke T. C-erbB-2 gene amplification: A molecular marker in recurrent bladder tumors? Cancer Res 1995; 55:2422-30.
31. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644-6.
32. Lee J, Dull TJ, Lax I, Schlessinger J, Ullrich A HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J 1989; 8:167-73.
33. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
34. Gorgoulis VG, Barbatis C, Poulias I, Karameris AM. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: A study in Greek patients. Mod Pathol 1995; 8:758-64.
35. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, Okuhara E, Akiyama T, Toyoshima K, Yamamoto T, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992; 70:2493-8.
36. Moriyama M, Akiyama T, Yamamoto T, Kawamoto T, Kato T, Sato K, Watanuki T, Hikage T, Katsuta N, Mori S. Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol 1991; 145:423-7.
37. Nakashima T, Sekiguchi T, Kuraoka A, Fukushima K, Shibata Y, Komiyama S, Nishimoto T. Molecular cloning of a human cDNA encoding a novel protein, DAD1, whose defect causes apoptotic cell death in hamster BHK21 cells. Mol Cell Biol 1993; 3:6367-6374.
38. Zhang H, Hoang T, Saeed B, Ng SC. Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases. Prostate 1996; 29:69-76.
39. Kelleher DJ, Gilmore R. DAD1, the defender against apoptotic cell death, is a subunit of the mammalian oligosaccharyltransferase. Proc Natl Acad Sci USA 1997; 94:4994-9.
40. Perez-Sala D, Mollinedo F. Inhibition of N-linked glycosylation induces early apoptosis in human promyelocytic HL-60 cells. J Cell Physiol 1995; 163:523-31.
41. Sabe H. Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion. J Biochem (Tokyo) 2003; 134:485-9.
42. Tague SE, Muralidharan V, D'Souza-Schorey C. ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci USA 2004; 101:9671-6.
43. El Sewedy T, Fornaro M, Alberti S. Cloning of the murine TROP2 gene: Conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer 1998; 75:324-30.
44. Fornaro M, Dell'Arciprete R, Stella M, Bucci C, Nutini M, Capri MG, Alberti S. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer 1995; 62:610-8.
45. Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998; 76:671-6.
46. Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MI. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987; 39:297-303.
47. Fradet Y, Cordon-Cardo C, Thomson T, Daly ME, Whitmore Jr WF, Lloyd KO, Melamed MR, Old LJ. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci USA 1984; 81:224-8.
48. Gerritsen ME, Soriano R, Yang S, Ingle G, Zlot C, Toy K, Winer J, Draksharapu A, Peale F, Wu TD, Williams PM. In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics 2002; 10:13-20.
49. Emoto Y, Kobayashi R, Akatsuka H, Hidaka H. Purification and characterization of a new member of the S-100 protein family from human placenta. Biochem Biophys Res Commun 1992; 182:1246-53.
50. Becker T, Gerke V, Kube E, Weber K. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca(2+) binding properties. Eur J Biochem 1992; 207:541-7.
51. Amler LC, Agus DB, LeDuc C, et al. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgenindependent prostate cancer xenograft model CWR22-R1. Cancer Res 2000; 60:6134-41.
52. Mousses S, Bubendorf L, Wagner U, et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 2002; 62:1256-60.
53. Da Silva IDCG, Fu Hu Y, Russo IH. S100P calciumbinding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int J Oncol 2000; 16:231-40.
54. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE. Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res 1997; 57:4111-7.
55. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol 1996; 155:2113-9.
56. Brouard MC, Saurat JH, Ghanem G, Siegenthaler G. Urinary excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma. Melanoma Res 2002; 12:027-31.